Evidence map›Paper›PMID 39281386›Full record

ArticleFrontiers in oncology2024

Intrinsic impacts of the expression of PD-L1 on postoperative recurrence in

Atsushi Ito, Shu Kano, Tomohito Tarukawa, Yuta Suzuki, Tadashi Sakaguchi, Kentaro Ito, Yoichi Nishii, Osamu Taguchi, Hiroki Yasui, Motoshi Takao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Atsushi ItoDepartment of Thoracic Surgery, Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Shu KanoDepartment of Thoracic Surgery, Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Tomohito TarukawaDepartment of Thoracic Surgery, Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Yuta SuzukiDepartment of Respiratory Medicine, Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Tadashi SakaguchiDepartment of Respiratory Medicine, Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Kentaro ItoDepartment of Respiratory Medicine, Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Yoichi NishiiDepartment of Respiratory Medicine, Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Osamu TaguchiDepartment of Respiratory Medicine, Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Hiroki YasuiDepartment of Respiratory Medicine, Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Motoshi TakaoDepartment of Thoracic and Cardiovascular Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Osamu HatajiDepartment of Respiratory Medicine, Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to assess the intrinsic impacts of the expression of PD-L1 on postoperative recurrence and the prognosis in patients with Patients and methods: Data from 221 surgically resected pathological stage IA-IIIA lung adenocarcinomas, collected between 2017 and 2019, were analyzed. This included measurements of Results: Among the patients, 140 were PD-L1-negative (<1%), while 81 were PD-L1-positive (≥1%). PD-L1 positivity was significantly associated with male sex (p=0.038), smoking habit (p=0.005), ND2 lymph node dissection (p=0.013), higher malignant subtype (p=0.003), higher histological grade (p=0.001), and advanced pathological stage (p=0.004). Conversely, Conclusion: PD-L1 positivity emerged as an independent risk factor for RFS in patients with

Indexed as

epidermal growth factor receptorlung adenocarcinomaoverall survivalpostoperative recurrenceprogrammed cell death ligand-1

Identifiers

PMID39281386
PMCPMC11392724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.